Status:
COMPLETED
The Effect of Xenical on Weight and Risk Factors
Lead Sponsor:
University of British Columbia
Conditions:
Obesity
Heart Diseases
Eligibility:
All Genders
19+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine the effect of using the weight loss medication Xenical (generic name - orlistat) on weight loss and change in heart disease risk factors in patients of the He...
Detailed Description
Obesity is associated with numerous chronic diseases and increased cardiovascular mortality. It is also an independent risk factor for cardiovascular disease (CVD) in addition to being associated with...
Eligibility Criteria
Inclusion
- Body mass index ≥ 27 with one risk factor for cardiovascular disease OR overweight/obese individuals with type 2 diabetes on standard hypoglycemic agents
- Recently prescribed Xenical at the St. Paul's Hospital Lipid Clinic
Exclusion
- Patients with previous experience using Xenical
- Patients currently using other weight loss medications.
- Unable to provide informed consent.
- Less than 19 years of age
Key Trial Info
Start Date :
June 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2013
Estimated Enrollment :
25 Patients enrolled
Trial Details
Trial ID
NCT00152360
Start Date
June 1 2005
End Date
March 1 2013
Last Update
April 1 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Healthy Heart Program/Lipid Clinic, St. Paul's Hospital
Vancouver, British Columbia, Canada